In an angiotensin II infusion model, a single intravenous injection of recombinant adeno-associated virus vector carrying thrombomodulin lectin-like domain (rAAV-TMD1) (1011 genome copies), which resulted in persistently elevated serum levels of TMD1 for at least 12 weeks, effectively inhibited AAA formation. The gene discussed is AGT; the disease is triple-A syndrome.